A Review of Capecitabine-Based Adjuvant Therapy for Gastric Cancer in the Chinese Population

References

• Ferlay J , SoerjomataramI, DikshitRet al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer136(5), e359–e386 (2015).
   PubMed Web of Science ®Google Scholar
• Chen W , ZhengR, BaadePDet al. Cancer statistics in China, 2015. CA Cancer J. Clin.66(2), 115–132 (2016).
   PubMed Web of Science ®Google Scholar
• Allemani C , WeirHK, CarreiraHet al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet385(9972), 977–1010 (2015).
   PubMed Web of Science ®Google Scholar
• Strong VE , WuAW, SelbyLVet al. Differences in gastric cancer survival between the US and China. J. Surg. Oncol.112(1), 31–37 (2015).
   PubMed Web of Science ®Google Scholar
• Smyth EC , VerheijM, AllumWet al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.27(Suppl. 5), V38–V49 (2016).
   PubMed Web of Science ®Google Scholar
• Sasaki E , MaedaY, SasakiT. [Comparison the standard therapies of gastric cancer in Japan with those in the west]. Gan To Kagaku Ryoho34(5), 700–704 (2007).
   PubMedGoogle Scholar
• Yang K , HuJK. Gastric cancer treatment: similarity and difference between China and Korea. Transl. Gastroenterol. Hepatol.2, 36 (2017).
   PubMedGoogle Scholar
• Noh SH , ParkSR, YangHKet al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised Phase III trial. Lancet Oncol.15(12), 1389–1396 (2014).
   PubMed Web of Science ®Google Scholar
• NCCN guidelines for gastric cancer . Version 1 (2017). www.nccn.org/.
   Google Scholar
• NCCN guidelines for gastric cancer . Chinese edition (2011). www.nccn.org/.
   Google Scholar
• Ji J , LiangH, ZhanYet al. [Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): Chinese subgroup analysis]. Zhonghua Wei Chang Wai Ke Za Zhi (Chinese J. Gastrointestinal Surg.)17(2), 133–138 (2014).
   PubMedGoogle Scholar
• Zhou YM . The efficacy of adjuvant chemotherapy of oxaliplatin plus capecitabine in stage II–III gastric cancer patients. Strait Pharm. J.7, 110–112 (2015).
   Google Scholar
• Zhou YM . The efficacy of adjuvant chemotherapy of oxaliplatin plus capecitabine in stage II–III gastric cancer patients. Strait Pharm. J.7, 110–112 (2015).
   Google Scholar
• Wu Y , WeiZW, HeYLet al. Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer. World J. Gastroenterol.19(21), 3309–3315 (2013).
   PubMed Web of Science ®Google Scholar
• Lei Z , LiH. Clinical observation of combination of oxaliplatin and capecitabine or oxaliplatin and 5-fluorouracil/leucovorin chemotherapy for local advanced gastric cancer. World Health Digest Medical Periodical9(22), 40–42 (2012).
   Google Scholar
• Chen S , FengX, LiY, YuanX, ZhouZ, ChenY. Efficacy and safety of XELOX and FOLFOX6 adjuvant chemotherapy following radical total gastrectomy. Oncol. Lett.3(4), 781–786 (2012).
   PubMed Web of Science ®Google Scholar
• Feng J , QinHF, WangBLet al. Value of oxaliplatin-based program in gastric cancer chemotherapy. Chin. J. Dig. Dis.33(4), 226–230 (2013).
   Google Scholar
• Zhang ZD , KongY, MaFet al. Adjuvant chemotherapy with oxaliplatin plus S-1 versus XELOX regimen for postoperative gastric cancer. Chin. J. Gen. Surg.22(6), 747–751 (2013).
   Google Scholar
• Li YF , ZhouZW, LiWet al. Comparison of capecitabine plus lobaplatin or oxaliplatin as adjuvant chemocherapy in advanced gastric cancer after D2 resection. Guangdong Medical Journal33(9), 1324–1327 (2012).
   Google Scholar
• MacDonald JS , SmalleySR, BenedettiJet al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med.345(10), 725–730 (2001).
   PubMed Web of Science ®Google Scholar
• Dikken JL , van SandickJW, Maurits SwellengrebelHAet al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer11, 329 (2011).
   PubMed Web of Science ®Google Scholar
• Velenik V , AnderluhF, OblakI, StrojanP, ZakotnikB. Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective Phase II trial. Croat. Med. J.47(5), 693–700 (2006).
   PubMed Web of Science ®Google Scholar
• Qiu H , DingFY, XiongHH, LiRC. A contrast research of concurrent chemoradiotherapy by capecitabine and 5-fluorouracil for gastric cancer. Herald of Medicine29(3), 306–309 (2010).
   Google Scholar
• Shi XG . The observation of capecitabine based concurrent chemoradiotherapy after radical gastrectomy. Journal of Clinical Medical3(17), 3477–3477 (2016).
   Google Scholar
• Chen BG , CaiYC, MoRK, LiuTQ, LiJX. Clinical study of three dimensional conformal radiation therapy plus capecitabine chemotherapy after radical gastrectomy. International Medicine & Health Guidance News18(7), 942–945 (2012).
   Google Scholar
• Guo P , ChenJF, HuangWet al. Observation on efficacy of docetaxel combined with capecitabine chemotherapy and concurrent radiochemotherapy in advanced gastric cancer after surgery. Evaluation and Analysis of Drug Use in Hospitals of China16(8), 1055–1057 (2016).
   Google Scholar
• Zhang YS , ZhaoCH, WangYMet al. Efficacy analysis of capecitabine based concurrent radiochemotherapy in 50 gastric cancer patients after surgery. China Pharmaceuticals5, 65–67 (2015).
   Google Scholar
• Yuan ST , WangFL, LiuNet al. Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence. Am. J. Clin. Oncol.38(2), 130–134 (2015).
   PubMed Web of Science ®Google Scholar
• Luo W , ZhangH, ZhaoYet al. A retrospective study on intensity-modulated radiation therapy combined with chemotherapy after D2 radical surgery for gastric carcinoma. Mol. Clin. Oncol.4(5), 740–748 (2016).
   PubMedGoogle Scholar
• Ren H , WangX, FangHet al. Interim assessment of prospective Phase II trial evaluating efficacy of intensity-modulated radiotherapy with concurrent capecitabine for stage II/III gastric cancer after radical surgery. Clin. J. Radiat. Oncol.23(2), 104–107 (2014).
   Google Scholar
• Wang YW , TangYW. A preliminary study on toxicity and efficacy of post-operative 3D radiotherapy plus capecitabine in treatment of patients with advanced gastric cancer. J. Clin. Exp. Med.11(16), 1283–1284 (2012).
   Google Scholar
• Wang X , JinJ, LiYXet al. Phase I trial of postoperative concurrent capecitabine and intensity-modulated radiotherapy for locally advanced gastric cancer. Chin. J. Radiat. Oncol.22(5), 343–346 (2013).
   Google Scholar
• Wang X , JinJ, LiYXet al. Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer. World J. Gastroenterol.20(4), 1067–1073 (2014).
   PubMed Web of Science ®Google Scholar
• Bickenbach K , StrongVE. Comparisons of gastric cancer treatments: east vs west. J. Gastric Cancer12(2), 55–62 (2012).
   PubMedGoogle Scholar
• Lee J , LimDH, KimSet al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J. Clin. Oncol.30(3), 268–273 (2012).
   PubMed Web of Science ®Google Scholar
• Foo M , LeongT. Adjuvant therapy for gastric cancer: current and future directions. World J. Gastroenterol.20(38), 13718–13727 (2014).
   PubMed Web of Science ®Google Scholar
• Li L , ZhangJH. Clinical efficacy of capecitabine treatment in elderly patients with advanced gastric cancer. Anti-tumor Pharmacy5, 379–380 (2012).
   Google Scholar
• Yuan X . Clinical application of capecitabine as adjuvant chemotherapy of gastric cancer in aged patients. Clinical Medicine of China25(7), 750–752 (2009).
   Google Scholar
• Bajetta E , ProcopioG, CelioLet al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J. Clin. Oncol.23(10), 2155–2161 (2005).
   PubMed Web of Science ®Google Scholar
• Feliu J , EscuderoP, LlosaFet al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz Cooperative Group study. J. Clin. Oncol.23(13), 3104–3111 (2005).
   PubMed Web of Science ®Google Scholar
• Coccolini F , CotteE, GlehenOet al. Intraperitoneal chemotherapy in advanced gastric cancer: meta-analysis of randomized trials. Eur. J. Surg. Oncol.40(1), 12–26 (2014).
   PubMed Web of Science ®Google Scholar
• Zhong L , CaiMD, WeiHJ, ZengH, LiJF. Clinical observation of intraperitoneal cisplatin plus oral capecitabine therapy in advanced gastric cancer patients after surgery. Youjiang Medical Journal40(3), 341–342 (2012).
   Google Scholar
• Wang SC , BaiW. Clinical observation of intraperitoneal docetaxel and cisplatin plus oral capecitabine therapy in gastric cancer patients with pyoperitoneum. Cancer Research and Clinic27(1), 55–56 (2015).
   Google Scholar
• Feng WM , TangCW, GuoHH, BaoY, FeiMY. Prolonged adjuvant capecitabine chemotherapy improved survival of stage IIIa gastric cancer after D2 gastrectomy. Biomed. Pharmacother.72, 140–143 (2015).
   PubMed Web of Science ®Google Scholar
• Qu J , RenXA, BianJL, TangSH. Capecitabine used for maintenance therapy of adjuvant chemotherapy after operation of late gastric cancer patients. China Medicine and Pharmacy1(9), 110 (2011).
   Google Scholar
• Cassidy J , SaltzL, TwelvesCet al. Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Ann. Oncol.22(12), 2604–2609 (2011).
   PubMed Web of Science ®Google Scholar
• Cassidy J , TwelvesC, Van CutsemEet al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann. Oncol.13(4), 566–575 (2002).
   PubMed Web of Science ®Google Scholar
• Hoff PM , AnsariR, BatistGet al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J. Clin. Oncol.19(8), 2282–2292 (2001).
   PubMed Web of Science ®Google Scholar
• Twelves C , GollinsS, GrieveR, SamuelL. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann. Oncol.17(2), 239–245 (2006).
   PubMed Web of Science ®Google Scholar
• Chen YP , HuSL. Analysis of the medical cost of capecitabine in treatment of advanced rectocolonic carcinoma. China Pharmacy15(7), 415–416 (2004).
   Google Scholar
• Wang L , LiuZH. Pharmacoeconomic evaluation of selective targeted oral chemotherapeutic agent Xeloda. Health Vocational Education24(3), 154–157 (2006).
   Google Scholar
• Wu B , LiT, CaiJ, XuY, ZhaoG. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer14, 984 (2014).
   PubMed Web of Science ®Google Scholar
• Sasako M , SakuramotoS, KataiHet al. Five-year outcomes of a randomized Phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J. Clin. Oncol.29(33), 4387–4393 (2011).
   PubMed Web of Science ®Google Scholar
• Li Z , FanB, ShanFet al. Gastrectomy in comprehensive treatment of advanced gastric cancer with synchronous liver metastasis: a prospectively comparative study. World J. Surg. Oncol.13, 212 (2015).
   PubMed Web of Science ®Google Scholar